, Volume 17, Issue 8, pp 784–796 | Cite as

Release of overexpressed CypB activates ERK signaling through CD147 binding for hepatoma cell resistance to oxidative stress

  • Kiyoon Kim
  • Hunsung Kim
  • Kwon Jeong
  • Min Hyung Jung
  • Bum-Soo Hahn
  • Kyung-Sik Yoon
  • Byung Kwan Jin
  • Geon-Ho Jahng
  • Insug Kang
  • Joohun Ha
  • Wonchae Choe
Original Paper


Cyclophilin, a cytosolic receptor for the immunosuppressive drug cyclosporin A, plays a role in diverse pathophysiologies along with its receptor, CD147. Although the interaction between cyclophilin A and CD147 is well established in inflammatory disease, that of cyclophilin B (CypB) with CD147 has not been fully explored, especially in cancer cell biology, and the exact molecular mechanism underlying such an association is poorly understood. In this study, we first identified high expression levels of CypB in 54 % of hepatocellular carcinoma patient tissues but in only 12.5 % of normal liver tissues. Then, we demonstrated that CypB overexpression protects human hepatoma cells against oxidative stress through its binding to CD147; this protective effect depends on the peptidyl prolyl isomerase activity of CypB. siRNA-mediated knockdown of CypB expression rendered hepatoma cells more vulnerable to ROS-mediated apoptosis. Furthermore, we also determined that a direct interaction between secreted CypB and CD147 regulates the extracellular signal-regulated kinase intracellular signaling pathway and is indispensible for the protective functions of CypB. For the first time, we demonstrated that CypB has an essential function in protecting hepatoma cells against oxidative stress through binding to CD147 and regulating the ERK pathway.


Cyclophilin B ROS Hepatoma cells CD147 ERK signaling PPIase activity Cyclosporin A 



This study was supported by the Basic Science Program through the National Research Foundation of Korea funded by the Ministry of Education, Science, and Technology (Grants 2009–0072431 and 20090063274) and by a grant from the Next-Generation BioGreen 21 Program (No. PJ008086), Rural Development Administration, Republic of Korea, and a grant of the Korean Heath Technology R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea (A092125).

Supplementary material

10495_2012_730_MOESM1_ESM.tif (1.3 mb)
Supplemental Fig. 1. a) Chang liver cells and Huh-7 cells were treated with 0, 0.4, 0.6 or 0.8 mM H2O2 for 24 h. After incubation, cell viability was measured by MTT assay. b) Chang cells were treated with 0, 0.4, 0.6 or 0.8 mM H2O2 for 24 h, and CypB mRNA levels were analyzed by real-time RT-PCR. c) Chang cells were transfected with a Mock, CypB/WT or CypB/R95A expression construct and treated with 0, 0.4, 0.6 or 0.8 mM H2O2 for 24 h. After incubation, cell viability was measured by MTT assay. Transfected cells were treated with 0.6 mM H2O2. After 24 h of incubation, cells were harvested, and apoptotic cells were detected with d) Annexin V/PI double staining and e) PI staining. Data are expressed as mean ± SD of three independent experiments. *, P<0.05 vs. Chang cells treated with H2O2; **, P<0.01 vs. Chang cells treated with H2O2; #, P<0.05 vs. mock-transfected cells treated with H2O2; ##, P<0.01 vs. mock-transfected cells treated with H2O2 (TIFF 1363 kb)


  1. 1.
    Bialecki ES, Di Bisceglie AM (2005) Diagnosis of hepatocellular carcinoma. HPB (Oxford) 7:26–34CrossRefGoogle Scholar
  2. 2.
    Omar HA, Chou CC, Berman-Booty LD et al (2011) Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma. Hepatology 53:1943–1958PubMedCrossRefGoogle Scholar
  3. 3.
    Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M (2006) Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 160:1–40PubMedCrossRefGoogle Scholar
  4. 4.
    Ridnour LA, Sim JE, Choi J et al (2005) Nitric oxide-induced resistance to hydrogen peroxide stress is a glutamate cysteine ligase activity-dependent process. Free Radic Biol Med 38:1361–1371PubMedCrossRefGoogle Scholar
  5. 5.
    Adachi M, Zhang Y, Zhao X et al (2004) Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells. Clin Cancer Res 10:3853–3862PubMedCrossRefGoogle Scholar
  6. 6.
    Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D (2006) The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 107:257–264PubMedCrossRefGoogle Scholar
  7. 7.
    Lecane PS, Karaman MW, Sirisawad M et al (2005) Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res 65:11676–11688PubMedCrossRefGoogle Scholar
  8. 8.
    Braaten D, Luban J (2001) Cyclophilin A regulates HIV-1 infectivity, as demonstrated by gene targeting in human T cells. EMBO J 20:1300–1309PubMedCrossRefGoogle Scholar
  9. 9.
    Brazin KN, Mallis RJ, Fulton DB, Andreotti AH (2002) Regulation of the tyrosine kinase Itk by the peptidyl-prolyl isomerase cyclophilin A. Proc Natl Acad Sci USA 99:1899–1904PubMedCrossRefGoogle Scholar
  10. 10.
    Colgan J, Asmal M, Neagu M et al (2004) Cyclophilin A regulates TCR signal strength in CD4 + T cells via a proline-directed conformational switch in Itk. Immunity 21:189–201PubMedCrossRefGoogle Scholar
  11. 11.
    Duina AA, Chang HC, Marsh JA, Lindquist S, Gaber RF (1996) A cyclophilin function in Hsp90-dependent signal transduction. Science 274:1713–1715PubMedCrossRefGoogle Scholar
  12. 12.
    Rycyzyn MA, Clevenger CV (2002) The intranuclear prolactin/cyclophilin B complex as a transcriptional inducer. Proc Natl Acad Sci USA 99:6790–6795PubMedCrossRefGoogle Scholar
  13. 13.
    Flisiak R, Dumont JM, Crabbe R (2007) Cyclophilin inhibitors in hepatitis C viral infection. Expert Opin Investig Drugs 16:1345–1354PubMedCrossRefGoogle Scholar
  14. 14.
    Yurchenko V, Constant S, Bukrinsky M (2006) Dealing with the family: CD147 interactions with cyclophilins. Immunology 117:301–309PubMedCrossRefGoogle Scholar
  15. 15.
    Fang F, Flegler AJ, Du P, Lin S, Clevenger CV (2009) Expression of cyclophilin B is associated with malignant progression and regulation of genes implicated in the pathogenesis of breast cancer. Am J Pathol 174:297–308PubMedCrossRefGoogle Scholar
  16. 16.
    Oh Y, Kim EY, Kim Y et al (2011) Neuroprotective effects of overexpressed cyclophilin B against Abeta-induced neurotoxicity in PC12 cells. Free Radic Biol Med 51(4):905–920PubMedCrossRefGoogle Scholar
  17. 17.
    Seizer P, Gawaz M, May AE (2008) Platelet-monocyte interactions—a dangerous liaison linking thrombosis, inflammation and atherosclerosis. Curr Med Chem 15:1976–1980PubMedCrossRefGoogle Scholar
  18. 18.
    Schmidt R, Bultmann A, Ungerer M et al (2006) Extracellular matrix metalloproteinase inducer regulates matrix metalloproteinase activity in cardiovascular cells: implications in acute myocardial infarction. Circulation 113:834–841PubMedCrossRefGoogle Scholar
  19. 19.
    Seizer P, Borst O, Langer HF et al (2009) EMMPRIN (CD147) is a novel receptor for platelet GPVI and mediates platelet rolling via GPVI-EMMPRIN interaction. Thromb Haemost 101:682–686PubMedGoogle Scholar
  20. 20.
    Jiang JL, Zhou Q, Yu MK, Ho LS, Chen ZN, Chan HC (2001) The involvement of HAb18G/CD147 in regulation of store-operated calcium entry and metastasis of human hepatoma cells. J Biol Chem 276:46870–46877PubMedCrossRefGoogle Scholar
  21. 21.
    Miyauchi T, Kanekura T, Yamaoka A, Ozawa M, Miyazawa S, Muramatsu T (1990) Basigin, a new, broadly distributed member of the immunoglobulin superfamily, has strong homology with both the immunoglobulin V domain and the beta-chain of major histocompatibility complex class II antigen. J Biochem 107:316–323PubMedGoogle Scholar
  22. 22.
    Kanekura T, Miyauchi T, Tashiro M, Muramatsu T (1991) Basigin, a new member of the immunoglobulin superfamily: genes in different mammalian species, glycosylation changes in the molecule from adult organs and possible variation in the N-terminal sequences. Cell Struct Funct 16:23–30PubMedCrossRefGoogle Scholar
  23. 23.
    Chen X, Lin J, Kanekura T et al (2006) A small interfering CD147-targeting RNA inhibited the proliferation, invasiveness, and metastatic activity of malignant melanoma. Cancer Res 66:11323–11330PubMedCrossRefGoogle Scholar
  24. 24.
    Li J, Peng L, Wu L et al (2010) Depletion of CD147 sensitizes human malignant melanoma cells to hydrogen peroxide-induced oxidative stress. J Dermatol Sci 58:204–210PubMedCrossRefGoogle Scholar
  25. 25.
    Komistek RD, Allain J, Anderson DT, Dennis DA, Goutallier D (2002) In vivo kinematics for subjects with and without an anterior cruciate ligament. Clin Orthop Relat Res 404:315–325PubMedCrossRefGoogle Scholar
  26. 26.
    Pakula R, Melchior A, Denys A, Vanpouille C, Mazurier J, Allain F (2007) Syndecan-1/CD147 association is essential for cyclophilin B-induced activation of p44/42 mitogen-activated protein kinases and promotion of cell adhesion and chemotaxis. Glycobiology 17:492–503PubMedCrossRefGoogle Scholar
  27. 27.
    Yurchenko V, O’Connor M, Dai WW et al (2001) CD147 is a signaling receptor for cyclophilin B. Biochem Biophys Res Commun 288:786–788PubMedCrossRefGoogle Scholar
  28. 28.
    Yurchenko V, Zybarth G, O’Connor M et al (2002) Active site residues of cyclophilin A are crucial for its signaling activity via CD147. J Biol Chem 277:22959–22965PubMedCrossRefGoogle Scholar
  29. 29.
    Obata Y, Yamamoto K, Miyazaki M, Shimotohno K, Kohno S, Matsuyama T (2005) Role of cyclophilin B in activation of interferon regulatory factor-3. J Biol Chem 280:18355–18360PubMedCrossRefGoogle Scholar
  30. 30.
    Yurchenko V, Constant S, Eisenmesser E, Bukrinsky M (2010) Cyclophilin-CD147 interactions: a new target for anti-inflammatory therapeutics. Clin Exp Immunol 160:305–317PubMedCrossRefGoogle Scholar
  31. 31.
    Saphire AC, Bobardt MD, Gallay PA (1999) Host cyclophilin A mediates HIV-1 attachment to target cells via heparans. EMBO J 18:6771–6785PubMedCrossRefGoogle Scholar
  32. 32.
    Carpentier M, Allain F, Haendler B et al (1999) Two distinct regions of cyclophilin B are involved in the recognition of a functional receptor and of glycosaminoglycans on T lymphocytes. J Biol Chem 274:10990–10998PubMedCrossRefGoogle Scholar
  33. 33.
    Kim J, Choi TG, Ding Y et al (2008) Overexpressed cyclophilin B suppresses apoptosis associated with ROS and Ca2+ homeostasis after ER stress. J Cell Sci 121:3636–3648PubMedCrossRefGoogle Scholar
  34. 34.
    Kim Y, Jang M, Lim S et al (2011) Role of cyclophilin B in tumorigenesis and cisplatin resistance in hepatocellular carcinoma in humans. Hepatology 54:1661–1678PubMedCrossRefGoogle Scholar
  35. 35.
    Lelie PN, van Drimmelen HA, Cuypers HT et al (2002) Sensitivity of HCV RNA and HIV RNA blood screening assays. Transfusion 42:527–536PubMedCrossRefGoogle Scholar
  36. 36.
    Melchior A, Denys A, Deligny A, Mazurier J, Allain F (2008) Cyclophilin B induces integrin-mediated cell adhesion by a mechanism involving CD98-dependent activation of protein kinase C-delta and p44/42 mitogen-activated protein kinases. Exp Cell Res 314:616–628PubMedCrossRefGoogle Scholar
  37. 37.
    Watashi K, Ishii N, Hijikata M et al (2005) Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell 19:111–122PubMedCrossRefGoogle Scholar
  38. 38.
    Fang F, Zheng J, Galbaugh TL et al (2010) Cyclophilin B as a co-regulator of prolactin-induced gene expression and function in breast cancer cells. J Mol Endocrinol 44:319–329PubMedCrossRefGoogle Scholar
  39. 39.
    Song F, Zhang X, Ren XB et al (2011) Cyclophilin A (CyPA) induces chemotaxis independent of its peptidylprolyl cistrans isomerase activity: direct binding between CyPA and the ectodomain of CD147. J Biol Chem 286:8197–8203PubMedCrossRefGoogle Scholar
  40. 40.
    Allain F, Vanpouille C, Carpentier M, Slomianny MC, Durieux S, Spik G (2002) Interaction with glycosaminoglycans is required for cyclophilin B to trigger integrin-mediated adhesion of peripheral blood T lymphocytes to extracellular matrix. Proc Natl Acad Sci USA 99:2714–2719PubMedCrossRefGoogle Scholar
  41. 41.
    Huynh H, Nguyen TT, Chow KH, Tan PH, Soo KC, Tran E (2003) Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol 3:19PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Kiyoon Kim
    • 1
  • Hunsung Kim
    • 1
  • Kwon Jeong
    • 1
  • Min Hyung Jung
    • 2
  • Bum-Soo Hahn
    • 3
    • 4
  • Kyung-Sik Yoon
    • 1
  • Byung Kwan Jin
    • 5
  • Geon-Ho Jahng
    • 6
  • Insug Kang
    • 1
  • Joohun Ha
    • 1
  • Wonchae Choe
    • 1
  1. 1.Department of Biochemistry and Molecular Biology, Medical Science and Engineering Research Center for Bioreaction to Reactive Oxygen Species, Biomedical Science Institute, School of MedicineKyung Hee UniversitySeoulKorea
  2. 2.Department of Obstetrics and Gynecology, School of MedicineKyung Hee UniversitySeoulKorea
  3. 3.National Academy of Agricultural ScienceSuwonKorea
  4. 4.Department of Genetic EngineeringKyung Hee UniversitySuwonKorea
  5. 5.Department of Biochemistry and Molecular Biology, Neurodegeneration Control Research Center, School of MedicineKyung Hee UniversitySeoulKorea
  6. 6.Department of Radiology, Kyung Hee University Hospital-Gangdong, School of MedicineKyung Hee UniversitySeoulKorea

Personalised recommendations